Stone Summit Wealth LLC Has $2.82 Million Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Stone Summit Wealth LLC boosted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 6.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 30,503 shares of the biopharmaceutical company’s stock after acquiring an additional 1,798 shares during the period. Stone Summit Wealth LLC’s holdings in Gilead Sciences were worth $2,818,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. HHM Wealth Advisors LLC raised its position in Gilead Sciences by 118.5% in the fourth quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 154 shares in the last quarter. nVerses Capital LLC acquired a new position in shares of Gilead Sciences in the 3rd quarter worth approximately $25,000. YANKCOM Partnership bought a new position in shares of Gilead Sciences during the 4th quarter worth approximately $28,000. Decker Retirement Planning Inc. acquired a new stake in Gilead Sciences in the 4th quarter valued at $29,000. Finally, Valued Wealth Advisors LLC raised its stake in Gilead Sciences by 101.9% during the third quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 161 shares in the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Insiders Place Their Bets

In related news, CFO Andrew D. Dickinson sold 248,645 shares of the business’s stock in a transaction on Friday, November 29th. The shares were sold at an average price of $92.76, for a total value of $23,064,310.20. Following the sale, the chief financial officer now directly owns 138,919 shares of the company’s stock, valued at approximately $12,886,126.44. The trade was a 64.16 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Jeffrey Bluestone sold 6,788 shares of the stock in a transaction dated Tuesday, November 26th. The stock was sold at an average price of $91.39, for a total value of $620,355.32. Following the transaction, the director now owns 8,920 shares of the company’s stock, valued at approximately $815,198.80. This trade represents a 43.21 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 572,824 shares of company stock worth $53,611,715 over the last ninety days. 0.16% of the stock is currently owned by corporate insiders.

Gilead Sciences Stock Down 2.0 %

Shares of NASDAQ:GILD opened at $96.04 on Monday. The company has a 50 day moving average price of $93.04 and a two-hundred day moving average price of $86.76. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.10 and a current ratio of 1.26. The company has a market capitalization of $119.69 billion, a PE ratio of 1,067.11, a PEG ratio of 1.25 and a beta of 0.18. Gilead Sciences, Inc. has a 52 week low of $62.07 and a 52 week high of $100.51.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, topping the consensus estimate of $1.58 by $0.44. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The business had revenue of $7.55 billion for the quarter, compared to the consensus estimate of $7.01 billion. During the same quarter last year, the business posted $2.29 EPS. The firm’s revenue was up 7.0% compared to the same quarter last year. Analysts forecast that Gilead Sciences, Inc. will post 4.35 earnings per share for the current year.

Wall Street Analyst Weigh In

GILD has been the topic of several analyst reports. Sanford C. Bernstein assumed coverage on shares of Gilead Sciences in a report on Thursday, October 17th. They issued an “outperform” rating and a $105.00 target price on the stock. Truist Financial upped their price objective on shares of Gilead Sciences from $83.00 to $97.00 and gave the stock a “hold” rating in a research note on Friday, November 8th. Wolfe Research assumed coverage on shares of Gilead Sciences in a research note on Friday, November 15th. They issued an “outperform” rating and a $110.00 target price for the company. Morgan Stanley upgraded Gilead Sciences from an “equal weight” rating to an “overweight” rating and increased their price target for the stock from $87.00 to $113.00 in a research report on Friday, January 10th. Finally, Maxim Group downgraded Gilead Sciences from a “buy” rating to a “hold” rating in a research report on Friday, November 8th. Eleven analysts have rated the stock with a hold rating, thirteen have given a buy rating and four have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $98.39.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.